 "Ind-Swift Lab zooms 83% in seven trading days on debt settlement hope")
Ind-Swift Laboratories is locked in upper circuit for the second straight day, up 10% at Rs 67.30, extending its six-session rally of over 60% on hopes of debt settlement.
The stock is trading at its 52-week high, zooming 83% in past seven trading sessions from Rs 36.80 on December 14, 2017. On comparison, the S&P BSE Sensex was up 2% during the same period.
The pharmaceutical company today said the company is in process of settlement of its debt through restructuring or OTS (one-time-settlement).
“We are at an advanced stage of the settlement with the Banks and Financial institutions with the help and assistance of the Asset Reconstruction Companies (ARCs). Already as mentioned in the financial statements few of the loan account have been settled through these ARCs. Once the debt resolution plan is through we expect a major financial restructuring of the debt profile of the Company. The same will also lead the Company to focus on the growth path through partnership, alliances & tie ups,” Ind-Swift Laboratories in 2016-17 annual report.
Till 01:46 PM; the trading volumes on the counter jumped more than three-fold with a combined 242,000 shares changed hands on the BSE. There were pending buy orders for 27,749 shares, the exchange data shows.
The stock is trading at its 52-week high, zooming 83% in past seven trading sessions from Rs 36.80 on December 14, 2017. On comparison, the S&P BSE Sensex was up 2% during the same period.
The pharmaceutical company today said the company is in process of settlement of its debt through restructuring or OTS (one-time-settlement).
“We are at an advanced stage of the settlement with the Banks and Financial institutions with the help and assistance of the Asset Reconstruction Companies (ARCs). Already as mentioned in the financial statements few of the loan account have been settled through these ARCs. Once the debt resolution plan is through we expect a major financial restructuring of the debt profile of the Company. The same will also lead the Company to focus on the growth path through partnership, alliances & tie ups,” Ind-Swift Laboratories in 2016-17 annual report.
Till 01:46 PM; the trading volumes on the counter jumped more than three-fold with a combined 242,000 shares changed hands on the BSE. There were pending buy orders for 27,749 shares, the exchange data shows.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%